Bolt Biotherapeutics (NASDAQ:BOLT) Issues Earnings Results

Bolt Biotherapeutics (NASDAQ:BOLT) announced its earnings results on Tuesday. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.04), Zacks reports. The company had revenue of $1.14 million during the quarter, compared to analysts’ expectations of $1.02 million. Bolt Biotherapeutics had a negative net margin of 592.57% and a negative return on equity of 61.40%.

Bolt Biotherapeutics Price Performance

Shares of BOLT traded down $0.01 during mid-day trading on Wednesday, hitting $0.63. The company’s stock had a trading volume of 20,256 shares, compared to its average volume of 165,189. The company has a current ratio of 4.28, a quick ratio of 4.28 and a debt-to-equity ratio of 0.19. Bolt Biotherapeutics has a 1-year low of $0.55 and a 1-year high of $1.56. The firm has a market capitalization of $24.11 million, a P/E ratio of -0.37 and a beta of 0.92. The firm has a 50-day simple moving average of $0.64 and a 200 day simple moving average of $0.74.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Bolt Biotherapeutics in a report on Wednesday. Five analysts have rated the stock with a hold rating, According to data from MarketBeat, Bolt Biotherapeutics currently has an average rating of “Hold” and an average price target of $3.50.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.